Mizuho Fukushige1,2, Margo Chase-Topping3, Mark E J Woolhouse4, Francisca Mutapi5,6. 1. Institute of Immunology and Infection Research, Centre for Immunity, Infection & Evolution, Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, United Kingdom. 2. Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. 3. Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, United Kingdom. 4. Usher Institute, University of Edinburgh, Edinburgh, United Kingdom. 5. Institute of Immunology and Infection Research, Centre for Immunity, Infection & Evolution, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom. 6. NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA), University of Edinburgh, Edinburgh, United Kingdom.
Abstract
BACKGROUND: The antihelminthic drug praziquantel has been used as the drug of choice for treating schistosome infection for more than 40 years. Although some epidemiological studies have reported low praziquantel efficacy in cure rate (CR) and/or egg reduction rate (ERR), there is no consistent robust evidence of the development of schistosome resistance to praziquantel (PZQ). There is need to determine factors that lead to variable treatment CR and/or ERR. Therefore, we conducted a systematic review and meta-analysis to review CR and ERR as well as identify their predictors. METHODOLOGY/PRINCIPAL FINDINGS: In this systematic review and meta-analysis, a literature review was conducted using Biosis Citation Index, Data Citation Index, MEDLINE, and Web of Science Core Collection all of which were provided through Web of Science. Alongside these, EMBASE, and CAB abstracts were searched to identify relevant articles. Random effect meta-regression models were used to identify the factors that influence CR and/or ERR by considering differences in host characteristics and drug dose. In total, 12,127 potential articles were screened and 146 eligible articles (published from 1979 to 2020) were identified and included for the meta-analysis. We found that there has been no significant reduction in CR or ERR over the study period. The results showed more variability in CR, compared with ERR which was more consistent and remained high. The results showed a positive effect of "PZQ treatment dose" with the current recommended dose of 40 mg/kg body weight achieving 57% to 88% CR depending on schistosome species, age of participants, and number of parasitological samples used for diagnosis, and ERR of 95%. CONCLUSIONS/SIGNIFICANCE: Based on a review of over 40 years of research there is no evidence to support concerns about schistosomes developing resistance to PZQ. These results indicate that PZQ remains effective in treating schistosomiasis.
BACKGROUND: The antihelminthic drug praziquantel has been used as the drug of choice for treating schistosome infection for more than 40 years. Although some epidemiological studies have reported low praziquantel efficacy in cure rate (CR) and/or egg reduction rate (ERR), there is no consistent robust evidence of the development of schistosome resistance to praziquantel (PZQ). There is need to determine factors that lead to variable treatment CR and/or ERR. Therefore, we conducted a systematic review and meta-analysis to review CR and ERR as well as identify their predictors. METHODOLOGY/PRINCIPAL FINDINGS: In this systematic review and meta-analysis, a literature review was conducted using Biosis Citation Index, Data Citation Index, MEDLINE, and Web of Science Core Collection all of which were provided through Web of Science. Alongside these, EMBASE, and CAB abstracts were searched to identify relevant articles. Random effect meta-regression models were used to identify the factors that influence CR and/or ERR by considering differences in host characteristics and drug dose. In total, 12,127 potential articles were screened and 146 eligible articles (published from 1979 to 2020) were identified and included for the meta-analysis. We found that there has been no significant reduction in CR or ERR over the study period. The results showed more variability in CR, compared with ERR which was more consistent and remained high. The results showed a positive effect of "PZQ treatment dose" with the current recommended dose of 40 mg/kg body weight achieving 57% to 88% CR depending on schistosome species, age of participants, and number of parasitological samples used for diagnosis, and ERR of 95%. CONCLUSIONS/SIGNIFICANCE: Based on a review of over 40 years of research there is no evidence to support concerns about schistosomes developing resistance to PZQ. These results indicate that PZQ remains effective in treating schistosomiasis.
Authors: Bonnie L Webster; Oumar T Diaw; Mohmoudane M Seye; Djibril S Faye; J Russell Stothard; Jose C Sousa-Figueiredo; David Rollinson Journal: Acta Trop Date: 2012-09-26 Impact factor: 3.112
Authors: Jana Kovač; Isabel Meister; Anna Neodo; Gordana Panic; Jean T Coulibaly; Christine Falcoz; Jennifer Keiser Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191
Authors: Frédéric D Chevalier; Winka Le Clec'h; Nina Eng; Anastasia R Rugel; Rafael Ramiro de Assis; Guilherme Oliveira; Stephen P Holloway; Xiaohang Cao; P John Hart; Philip T LoVerde; Timothy J C Anderson Journal: Int J Parasitol Date: 2016-04-09 Impact factor: 3.981
Authors: Piero L Olliaro; Michel Vaillant; Aïssatou Diawara; Jean T Coulibaly; Amadou Garba; Jennifer Keiser; Charles H King; Stefanie Knopp; Aly Landouré; Eliézer K N'Goran; Giovanna Raso; Alexandra U Scherrer; José Carlos Sousa-Figueiredo; Katarina Stete; Xiao-Nong Zhou; Jürg Utzinger Journal: PLoS Negl Trop Dis Date: 2015-06-18
Authors: José C Sousa-Figueiredo; Martha Betson; Aaron Atuhaire; Moses Arinaitwe; Annalan M D Navaratnam; Narcis B Kabatereine; Quentin Bickle; J Russell Stothard Journal: PLoS Negl Trop Dis Date: 2012-10-18
Authors: Evgeny G Chulkov; Emery Smith; Claudia M Rohr; Nawal A Yahya; Sang-Kyu Park; Louis Scampavia; Timothy P Spicer; Jonathan S Marchant Journal: PLoS Negl Trop Dis Date: 2021-11-03
Authors: Tom L Gallinger; Samuel Y Aboagye; Wiebke Obermann; Michael Weiss; Arnold Grünweller; Carlo Unverzagt; David L Williams; Martin Schlitzer; Simone Haeberlein Journal: Pharmaceuticals (Basel) Date: 2022-01-19
Authors: Martin Walker; Luzia T Freitas; Julia B Halder; Matthew Brack; Jennifer Keiser; Charles H King; Bruno Levecke; Yvonne Ai-Lian Lim; Otavio Pieri; Doudou Sow; J Russell Stothard; Joanne P Webster; Xiao-Nong Zhou; Robert F Terry; Philippe J Guérin; Maria-Gloria Basáñez Journal: Wellcome Open Res Date: 2022-01-05
Authors: Tushabe John Vianney; Duncan J Berger; Stephen R Doyle; Geetha Sankaranarayanan; Joel Serubanja; Prossy Kabuubi Nakawungu; Fred Besigye; Richard E Sanya; Nancy Holroyd; Fiona Allan; Emily L Webb; Alison M Elliott; Matthew Berriman; James A Cotton Journal: PLoS Negl Trop Dis Date: 2022-08-18
Authors: Duncan J Berger; Thomas Crellen; Poppy H L Lamberton; Fiona Allan; Alan Tracey; Jennifer D Noonan; Narcis B Kabatereine; Edridah M Tukahebwa; Moses Adriko; Nancy Holroyd; Joanne P Webster; Matthew Berriman; James A Cotton Journal: Nat Commun Date: 2021-08-06 Impact factor: 14.919